| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/22/2004 | US20040142871 Osteoporosis treatment |
| 07/22/2004 | US20040142859 Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
| 07/22/2004 | US20040142852 vitamin; a metal salt that provides metal ions in vivo; and insulin or a growth hormone |
| 07/22/2004 | US20040142851 by inducing the apoptosis according to a inhibition mechanism of the enzyme activities of proteasome |
| 07/22/2004 | US20040142807 having at least one arm assembly that rotates in a vertical plane and extends outward on a common radius from a horizontal axis of rotation; independently controlling speed of rotation and speed of removal of the heavy material |
| 07/22/2004 | US20040142469 Nucleotide sequences comprising unmethylated cytosine and guaninedinucleotides for use as antisense tools in treatment and prevention of viral diseases; viricides |
| 07/22/2004 | US20040142466 Extending tissue preservation |
| 07/22/2004 | US20040142465 Injectable hyaluronic acid derivative with pharmaceuticals/cells |
| 07/22/2004 | US20040142431 Nucleotide sequences comprising restriction fragment length polymorphisms coding polypeptide with antiproliferative, antiviral and antiparasitic effects |
| 07/22/2004 | US20040142394 Method for diagnosing a tumor in a patient determining the concentration of PIBF |
| 07/22/2004 | US20040142391 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with RAGE |
| 07/22/2004 | US20040142388 Method for detecting chronic dementia diseases, and corresponding VGF peptides and detection reagents |
| 07/22/2004 | US20040142377 dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance and type 2 diabetes |
| 07/22/2004 | US20040142317 Use of amino acid transporter atbo,+ as a delivery system for drugs and prodrugs |
| 07/22/2004 | US20040142094 Method for coating medical devices |
| 07/22/2004 | US20040142048 e.g., blue fruit extracts with epigallocatechin gallate, epicatechin, epicatechin gallate, or epigallocatechin; treating primary and metastatic cancers |
| 07/22/2004 | US20040142047 Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof |
| 07/22/2004 | US20040142041 alumina particles, silica particles or alumina coated particles as carrier having a functional compound adsorbed on the surface that is released when exposed to an environmental or chemical condition |
| 07/22/2004 | US20040142040 Formulation and dosage form providing increased bioavailability of hydrophobic drugs |
| 07/22/2004 | US20040142038 Three layer artificial tear formulation |
| 07/22/2004 | US20040142036 unit aliquot dose of a pharmaceutical electricstatically deposited on a porous, permeable or semi-permeable ingestible membrane; including two or more active pharmaceuticals segregated from one another in a single delivery package. |
| 07/22/2004 | US20040142035 Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics |
| 07/22/2004 | US20040142034 Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators |
| 07/22/2004 | US20040142033 releases the following quantities of oxcarbazepine:15 min: 55 to 85%30 min: 75 to 95%45 min: 85 to 100%60 min: 90 to 100%in vitro |
| 07/22/2004 | US20040142032 treating of ulcers and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome; free of (+) isomer; inhibits H+,K+-ATPase with out the adverse effects seen upon administration of racemic pantoprazole. |
| 07/22/2004 | US20040142031 carrier containing more than 10% by weight of a water-insoluble starch; shelf-life under relatively dry circumstances is enhanced. |
| 07/22/2004 | US20040142030 Stabilized tibolone compositions |
| 07/22/2004 | US20040142029 cellulose polymer, a methacrylic polymer and an active ingredient homogeniously distributed in a molecular state in an atomized matrix; also contains an organic base or an alkaline salt; and an adsorbent |
| 07/22/2004 | US20040142028 carrier containing more than 10% by weight of a water-insoluble starch; shelf-life under relatively dry circumstances is enhanced. |
| 07/22/2004 | US20040142027 vehicle comprising; a modified unsaturated oil and, optionally, a non-oxidizable oil; immediately after manufacture, composition can be administered such that the bioactive agents are released to the host on a predictable sustained basis. |
| 07/22/2004 | US20040142026 pulmonary administration of a liposomal/complexed antiinfective to treat or ameliorate a pulmonary infection in a cystic fibrosis patient; administrated amount is 50% or less of the comparative free drug amount |
| 07/22/2004 | US20040142022 exposure to electron beam radiation, preferably low level electron beam radiation, to produce sterilized patch for transdermal delivery |
| 07/22/2004 | US20040142021 System and methods for local intradermal treatment |
| 07/22/2004 | US20040142018 Regulator for amount of body fat |
| 07/22/2004 | US20040142013 solid component such as a surgical screw with indentations formed in its surface and spherical particles bound to the indentation that are designed to provide controlled release of antimicrobial compound to treat osteomyelitis. |
| 07/22/2004 | US20040142000 Immune activator |
| 07/22/2004 | US20040141973 IPG antagonists for the treatment of conditions involving mast cells, basophils and eosinophils |
| 07/22/2004 | US20040141954 composition comprising a daidzein-containing substance and a strain of microorganism capable of metabolizing daidzein to equol as essential ingredients |
| 07/22/2004 | US20040141950 Immunostimulatory combinations |
| 07/22/2004 | US20040141949 Treatment of mucositis |
| 07/22/2004 | US20040141945 novel material which combines cell-adhesive proteins such as collagen with GAG polymers to construct an environment similar to an extracellular matrix, capable of controlling differentiation and proliferation of cells |
| 07/22/2004 | US20040141944 polymer synthesized by a cross-coupling reaction of polymer scaffold units and xenoantigens |
| 07/22/2004 | US20040141935 applying an emulsion containing a compound that inhibits hair growth to skin wherein the emulsion has been prepared using a phase inversion procedure |
| 07/22/2004 | US20040141925 Nanoparticles; therapy of arthritis, skin disorders, blood disorders, kidney disorders, eye disorders, thyroid, intestinal disorders, cancer, allergic reactions, asthma, contact dermatitis, atopic dermatitis, seasonal allergic rhinitis |
| 07/22/2004 | US20040141924 Administering an antiasthmatic-effective amount of a MEK inhibitor to a patient in need of treatment, or to a patient suspected of developing asthma and in need of prophylactic treatment |
| 07/22/2004 | US20040141923 propellant free; for transmucosal administration |
| 07/22/2004 | US20040141918 Nucleotide and deduced amino acid sequences of tumor gene Int6 |
| 07/22/2004 | US20040141912 Administering medicinally-useful agent which is phospholipid scramblase (PLS)-dependent transported compound to cells, thereby causing selective transport of agent into cells |
| 07/22/2004 | US20040139908 Formation of small crystals |
| 07/22/2004 | DE202004003404U1 Pharmazeutische Zusammensetzung zur kontrollierten Freisetzung von Wirkstoffen A pharmaceutical composition for controlled release of active ingredients |
| 07/22/2004 | DE10340684A1 Topical cosmetic or pharmaceutical compositions for increasing collagen expression in skin cells, useful e.g. for improving stability and strength of skin, containing vitamin B6 as active agent |
| 07/22/2004 | DE10301105A1 2-Amino-2H-chinazolin-Derivat und dessen pharmazeutisch verträgliche Salze zur Anwendung als therapeutische Werkstoffe sowie diese Wirkstoffe enthaltende pharmazeutische Präparate 2-amino-2H-quinazoline derivatives and their pharmaceutically acceptable salts for use as therapeutic materials containing these active substances as well as pharmaceutical preparations |
| 07/22/2004 | DE10300973A1 Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung New carboxylic acids and esters thereof, pharmaceutical compositions containing them and processes for their preparation |
| 07/22/2004 | DE10300398A1 Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel Use of substituted 2-Phenylbenzimidazolen as drugs |
| 07/22/2004 | CA2764405A1 Pharmaceutical preparations for treatments of diseases and disorders of the breast |
| 07/22/2004 | CA2724305A1 Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
| 07/22/2004 | CA2708895A1 Compositions, methods and kits useful for the alleviation of gastrointestinal side effects of lipase inhibitors |
| 07/22/2004 | CA2552261A1 Cardioprotective delta opioid receptor agonists and methods of using same |
| 07/22/2004 | CA2514477A1 Novel factor viia inhibiting compounds |
| 07/22/2004 | CA2513627A1 Anti-inflammatory medicaments |
| 07/22/2004 | CA2512558A1 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells |
| 07/22/2004 | CA2512346A1 Imino acid derivatives for use as inhibitors of matrix metalloproteinases |
| 07/22/2004 | CA2512056A1 Drug-coated stents and methods of use therefor |
| 07/22/2004 | CA2512049A1 Method of treatment for central nervous system injury |
| 07/22/2004 | CA2511905A1 Novel cb 1 receptor inverse agonists |
| 07/22/2004 | CA2511881A1 Pharmaceutical compositions comprising a sodium salt of celecoxib with improved dissolution |
| 07/22/2004 | CA2511873A1 Modulation of protein functionalities |
| 07/22/2004 | CA2511859A1 Novel cb 1 receptor inverse agonists |
| 07/22/2004 | CA2511840A1 Anti-cancer medicaments |
| 07/22/2004 | CA2511816A1 Methods and compositions for the diagnosis, prognosis, and treatment of cancer |
| 07/22/2004 | CA2511737A1 Body weight gain inhibitor |
| 07/22/2004 | CA2511646A1 Thiosemicarbazones as anti-virals and immunopotentiators |
| 07/22/2004 | CA2511555A1 Aerosolizable pharmaceutical formulation for fungal infection therapy |
| 07/22/2004 | CA2511540A1 Acid labile drug compositions |
| 07/22/2004 | CA2511538A1 Immunostimulatory combinations |
| 07/22/2004 | CA2511523A1 Pharmaceutical formulation with an insoluble active agent for pulmonary administration |
| 07/22/2004 | CA2511385A1 Non-hygroscopic formulation comprising a hydroscopic drug |
| 07/22/2004 | CA2510903A1 Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 07/22/2004 | CA2510584A1 Combination of reboxetine and a cyclooxygenase-2 inhibitor |
| 07/22/2004 | CA2510051A1 Derivatives of prostaglandins for treating abdominal discomfort |
| 07/22/2004 | CA2510042A1 Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same |
| 07/22/2004 | CA2509758A1 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 07/22/2004 | CA2509731A1 Treatment of hiv infection through combined administration of tipranavir and capravirine |
| 07/22/2004 | CA2509261A1 Solid dispersions comprising a hygroscopic and/or deliquescent drug |
| 07/22/2004 | CA2509232A1 Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
| 07/22/2004 | CA2508884A1 A method for the treatment, prevention, or inhibition of a cns disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| 07/22/2004 | CA2508127A1 Compounds that bind p2y2 or p2y1 receptors |
| 07/22/2004 | CA2507971A1 Compositions, methods, and kits useful for the alleviation of gastrointestinal side effects of lipase inhibitors |
| 07/22/2004 | CA2506719A1 Treatment of chronic heart failure |
| 07/22/2004 | CA2455832A1 Method for dip coating medical devices with an aqueous latex polymeric emulsion |
| 07/21/2004 | EP1439229A2 Oncogene, recombinant protein derived therefrom, and uses thereof |
| 07/21/2004 | EP1439190A1 Growth differentiation factor-5 |
| 07/21/2004 | EP1439185A1 Stabilization of amrubicin hydrochloride |
| 07/21/2004 | EP1439179A1 New oripavine derivatives and their uses as medicines |
| 07/21/2004 | EP1439178A1 HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF |
| 07/21/2004 | EP1439177A1 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| 07/21/2004 | EP1439176A1 Pyrimidone compounds and pharmaceutical compositions containing the same |
| 07/21/2004 | EP1439175A1 Pyrimidine compound and medicinal composition thereof |
| 07/21/2004 | EP1439174A1 4-imidazolin-2-one compounds |
| 07/21/2004 | EP1439172A1 Method of obtaining 2-(2-nitrovinyl)-furan and the use thereof as a coccidiostatic |